Evotec Reports Third Quarter and Nine-Month 2026 Results: Building Growth Momentum Toward 2030 Goals

Evotec SE announced its Q3 and nine-month 2026 financial results, reaffirming full-year guidance while setting 2030 targets of €1 billion revenue and over 20% EBITDA margin. Key developments include advancements in its biologics platform and new research collaborations.